3 Alarming Facts About Cystic Fibrosis Amphotericin Treatment Research
Researchers have found that amphotericin, a widely used antifungal medication, may hold significant promise as a cystic fibrosis amphotericin treatment approach that works regardless of the type of genetic mutation involved. Published in the journal Nature and supported in part by the National Heart, Lung, and Blood Institute at the National Institutes of Health, the study used human lung cells and animal models to demonstrate that amphotericin can restore lung function in ways that existing treatments cannot. According to the Mayo Clinic, cystic fibrosis is a life threatening genetic disorder affecting more than 30,000 people in the United States and 70,000 worldwide, with no cure currently available.
Why Existing Cystic Fibrosis Treatments Are Limited
Cystic fibrosis is caused by a defect in the CFTR gene, which normally produces a protein that controls the movement of salt, bicarbonate, and water in and out of cells. When the gene is defective, the resulting abnormal protein causes a buildup of acidic, sticky mucus that clogs the lungs, makes breathing difficult, and leaves patients highly vulnerable to chronic bacterial infections.
Current treatments are limited in a critical way: they are designed to address specific types of mutated CFTR proteins. This means patients with different mutations may not respond, and approximately 10% of people with cystic fibrosis produce no CFTR protein at all, making them ineligible for most available therapies. The cystic fibrosis amphotericin treatment approach addresses this gap directly.
How Amphotericin Works as a Molecular Prosthetic
Rather than correcting or replacing the defective CFTR protein, the cystic fibrosis amphotericin treatment strategy uses the drug as what lead researcher Martin Burke, MD, PhD, professor of chemistry at the University of Illinois, describes as a molecular prosthetic. Amphotericin forms channels in lung cell membranes that mimic the function of the missing or defective CFTR protein, allowing bicarbonate and other materials to move in and out of cells normally.
This approach is fundamentally different from gene therapy, which has not yet proven effective in the lung. Because amphotericin substitutes for the protein’s channel function rather than trying to correct the underlying genetic defect, it has the potential to work across all mutation types and even in patients who produce no CFTR protein at all.
3 Alarming Facts About the Cystic Fibrosis Amphotericin Treatment Findings
1. Amphotericin Restored Key Markers of Lung Function in Cystic Fibrosis Tissue
In studies using lung tissue from cystic fibrosis patients as well as pig models of the disease, the cystic fibrosis amphotericin treatment produced a range of improvements associated with healthier lung function. These included restoration of normal pH levels in the airway surface liquid, improved mucus viscosity, and increased antibacterial activity. Each of these changes addresses a distinct aspect of the disease process that drives both breathing difficulty and infection susceptibility.
2. The Drug Could Reach the 10% of Patients No Treatment Currently Helps
One of the most significant aspects of the cystic fibrosis amphotericin treatment is its potential applicability to the roughly 10% of cystic fibrosis patients who do not respond to any existing therapy because they produce no functional CFTR protein. Because amphotericin bypasses the protein entirely by performing its channel function directly, this subgroup of patients, who currently have no effective treatment options, could potentially benefit.
3. Amphotericin Is Already FDA Approved and Available
A critical practical advantage of the cystic fibrosis amphotericin treatment is that amphotericin is already an approved and commercially available medication used to treat fungal infections. As Burke noted, this existing approval status makes it a strong candidate for faster development toward clinical use compared to entirely new molecular entities that must complete the full regulatory pathway from scratch. The drug can also be delivered directly to the lungs to minimize systemic side effects.
What Comes Next
The researchers and NIH experts alike have emphasized that additional experimental studies are needed before cystic fibrosis amphotericin treatment can be tested safely in human clinical trials. James Kiley, PhD, director of the Division of Lung Diseases at NHLBI, expressed interest in seeing how this potential treatment performs as it moves toward clinical trial evaluation.
FOMAT conducts Phase I through Phase IV clinical research across a national network of investigator sites throughout the United States. To learn more about active respiratory and rare disease studies, visit our patient active studies page.